This memorandum titled What to Expect Next in Health Care Policy provides insight on what to expect next in health care policy following last week’s
Here is a memo summarizing the Trump administration’s proposed budget for FY 2018. Notably, the budget lists funding for Ryan White providers as one of
The Health Resources and Services Administration (HRSA) has delayed until May 22, 2017 the effective date of the 340B Drug Pricing Program Ceiling Price and
The Alliance for Integrity and Reform of 340B (AIR-340B), an advocacy group funded by the pharmaceutical industry and oncologists, has told Congress how to scale
House Republicans released last night a draft plan for repeal and replace of the Affordable Care Act (ACA). The House Energy and Commerce Committee and
The U.S. Government and Accountability Office (GAO) is examining 340B contract pharmacy arrangements, although we do not yet know the purpose of the GAO’s review.
Several manufacturers of leading antiretroviral drugs increased wholesale acquisition cost (WAC) prices at the beginning of this year, despite an open letter submitted by the
